JP 1302 dihydrochlorideCAS# 1259314-65-2 |
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- CC-401 hydrochloride
Catalog No.:BCC1458
CAS No.:1438391-30-0
- AS 602801
Catalog No.:BCC1369
CAS No.:848344-36-5
- CC-930
Catalog No.:BCC1459
CAS No.:899805-25-5
- DB07268
Catalog No.:BCC1519
CAS No.:929007-72-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1259314-65-2 | SDF | Download SDF |
| PubChem ID | 49855035 | Appearance | Powder |
| Formula | C24H26Cl2N4 | M.Wt | 441.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in water and to 5 mM in DMSO | ||
| Chemical Name | N-[4-(4-methylpiperazin-1-yl)phenyl]acridin-9-amine;dihydrochloride | ||
| SMILES | CN1CCN(CC1)C2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53.Cl.Cl | ||
| Standard InChIKey | VVZOADYFJAJZGL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H24N4.2ClH/c1-27-14-16-28(17-15-27)19-12-10-18(11-13-19)25-24-20-6-2-4-8-22(20)26-23-9-5-3-7-21(23)24;;/h2-13H,14-17H2,1H3,(H,25,26);2*1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | α2C-adrenoceptor antagonist that displays ~ 50-fold selectivity over other α2-adrenoceptor subtypes (Ki values are 28, 1470, 1700 and 3150 nM for human α2C, α2B, α2D and α2A subtypes respectively). Potently antagonizes adrenalin-stimulated 35GTPγS binding in vitro (KB = 16 nM) and produces antidepressant and antipsychotic-like effects in vivo. |
JP 1302 dihydrochloride Dilution Calculator
JP 1302 dihydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2655 mL | 11.3276 mL | 22.6552 mL | 45.3104 mL | 56.638 mL |
| 5 mM | 0.4531 mL | 2.2655 mL | 4.531 mL | 9.0621 mL | 11.3276 mL |
| 10 mM | 0.2266 mL | 1.1328 mL | 2.2655 mL | 4.531 mL | 5.6638 mL |
| 50 mM | 0.0453 mL | 0.2266 mL | 0.4531 mL | 0.9062 mL | 1.1328 mL |
| 100 mM | 0.0227 mL | 0.1133 mL | 0.2266 mL | 0.4531 mL | 0.5664 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SAMS Peptide
Catalog No.:BCC5745
CAS No.:125911-68-4
- 24-Methylenecycloartanol acetate
Catalog No.:BCN6137
CAS No.:1259-94-5
- (+)-Glaucarubinone
Catalog No.:BCN7956
CAS No.:1259-86-5
- LY2940680
Catalog No.:BCC3935
CAS No.:1258861-20-9
- 9-O-Ethyldeacetylorientalide
Catalog No.:BCN7311
CAS No.:1258517-60-0
- Deacetylorientalide
Catalog No.:BCN7310
CAS No.:1258517-59-7
- Parathyroid Hormone (1-34), bovine
Catalog No.:BCC1040
CAS No.:12583-68-5
- Pristimerin
Catalog No.:BCN2315
CAS No.:1258-84-0
- CEP-33779
Catalog No.:BCC2199
CAS No.:1257704-57-6
- Amikacin hydrate
Catalog No.:BCC4621
CAS No.:1257517-67-1
- TBA354
Catalog No.:BCC6459
CAS No.:1257426-19-9
- TC-E 5006
Catalog No.:BCC7981
CAS No.:1257395-14-4
- VU 0155041 sodium salt
Catalog No.:BCC7642
CAS No.:1259372-69-4
- SCH 23390 hydrochloride
Catalog No.:BCC6849
CAS No.:125941-87-9
- 10-O-Ethylcannabitriol
Catalog No.:BCN7312
CAS No.:1259515-25-7
- Griseofulvin
Catalog No.:BCC5327
CAS No.:126-07-8
- Solasodine
Catalog No.:BCN2346
CAS No.:126-17-0
- Sarsasapogenin
Catalog No.:BCN1269
CAS No.:126-19-2
- Oxethazaine
Catalog No.:BCC3832
CAS No.:126-27-2
- Polygalic acid
Catalog No.:BCN3172
CAS No.:1260-04-4
- Phlegmanol C
Catalog No.:BCN6138
CAS No.:1260-05-5
- Carminic acid
Catalog No.:BCN6541
CAS No.:1260-17-9
- 28-Deoxonimbolide
Catalog No.:BCN4717
CAS No.:126005-94-5
- TAK-438
Catalog No.:BCC1182
CAS No.:1260141-27-2
Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302.[Pubmed:17220913]
Br J Pharmacol. 2007 Feb;150(4):391-402.
BACKGROUND AND PURPOSE: Pharmacological validation of novel functions for the alpha2A-, alpha2B-, and alpha2C-adrenoceptor (AR) subtypes has been hampered by the limited specificity and subtype-selectivity of available ligands. The current study describes a novel highly selective alpha2C-adrenoceptor antagonist, JP-1302 (acridin-9-yl-[4-(4-methylpiperazin-1-yl)-phenyl]amine). EXPERIMENTAL APPROACH: Standard in vitro binding and antagonism assays were employed to demonstrate the alpha2C-AR specificity of JP-1302. In addition, JP-1302 was tested in the forced swimming test (FST) and the prepulse-inhibition of startle reflex (PPI) model because mice with genetically altered alpha2C-adrenoceptors have previously been shown to exhibit different reactivity in these tests when compared to wild-type controls. KEY RESULTS: JP-1302 displayed antagonism potencies (KB values) of 1,500, 2,200 and 16 nM at the human alpha2A-, alpha2B-, and alpha2C-adrenoceptor subtypes, respectively. JP-1302 produced antidepressant and antipsychotic-like effects, i.e. it effectively reduced immobility in the FST and reversed the phencyclidine-induced PPI deficit. Unlike the alpha2-subtype non-selective antagonist atipamezole, JP-1302 was not able to antagonize alpha2-agonist-induced sedation (measured as inhibition of spontaneous locomotor activity), hypothermia, alpha2-agonist-induced mydriasis or inhibition of vas deferens contractions, effects that have been generally attributed to the alpha2A-adrenoceptor subtype. In contrast to JP-1302, atipamezole did not antagonize the PCP-induced prepulse-inhibition deficit. CONCLUSIONS AND IMPLICATIONS: The results provide further support for the hypothesis that specific antagonism of the alpha2C-adrenoceptor may have therapeutic potential as a novel mechanism for the treatment of neuropsychiatric disorders.
JP-1302: a new tool to shed light on the roles of alpha2C-adrenoceptors in brain.[Pubmed:17220912]
Br J Pharmacol. 2007 Feb;150(4):381-2.
The discovery of JP-1302 as a selective, high affinity antagonist at the alpha2C-adrenoceptor will enable researchers to probe the functional role and address the therapeutic utility of this potentially highly important adrenoceptor subtype.
